484 related articles for article (PubMed ID: 27671693)
1. Finding the balance between over- and under-treatment of ductal carcinoma in situ (DCIS).
Groen EJ; Elshof LE; Visser LL; Rutgers EJT; Winter-Warnars HAO; Lips EH; Wesseling J
Breast; 2017 Feb; 31():274-283. PubMed ID: 27671693
[TBL] [Abstract][Full Text] [Related]
2. Modeling the natural history of ductal carcinoma in situ based on population data.
Chootipongchaivat S; van Ravesteyn NT; Li X; Huang H; Weedon-Fekjær H; Ryser MD; Weaver DL; Burnside ES; Heckman-Stoddard BM; de Koning HJ; Lee SJ
Breast Cancer Res; 2020 May; 22(1):53. PubMed ID: 32460821
[TBL] [Abstract][Full Text] [Related]
3. Controversies in the Treatment of Ductal Carcinoma in Situ.
Barrio AV; Van Zee KJ
Annu Rev Med; 2017 Jan; 68():197-211. PubMed ID: 28099081
[TBL] [Abstract][Full Text] [Related]
4. Risk of invasive breast carcinoma among women diagnosed with ductal carcinoma in situ and lobular carcinoma in situ, 1988-2001.
Li CI; Malone KE; Saltzman BS; Daling JR
Cancer; 2006 May; 106(10):2104-12. PubMed ID: 16604564
[TBL] [Abstract][Full Text] [Related]
5. Ductal Carcinoma In Situ - Quo Vadis?
Peltecu G
Chirurgia (Bucur); 2021 Dec; 116(5 Suppl):S5-S6. PubMed ID: 34967322
[TBL] [Abstract][Full Text] [Related]
6. Avoiding Overtreatment of Ductal Carcinoma in situ.
van der Borden CL; Stoffers S; Lips EH; Wesseling J
Trends Cancer; 2019 Jul; 5(7):391-393. PubMed ID: 31311652
[TBL] [Abstract][Full Text] [Related]
7. The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening.
van Luijt PA; Heijnsdijk EA; Fracheboud J; Overbeek LI; Broeders MJ; Wesseling J; den Heeten GJ; de Koning HJ
Breast Cancer Res; 2016 May; 18(1):47. PubMed ID: 27160733
[TBL] [Abstract][Full Text] [Related]
8. Ductal carcinoma in situ: to treat or not to treat, that is the question.
van Seijen M; Lips EH; Thompson AM; Nik-Zainal S; Futreal A; Hwang ES; Verschuur E; Lane J; Jonkers J; Rea DW; Wesseling J;
Br J Cancer; 2019 Aug; 121(4):285-292. PubMed ID: 31285590
[TBL] [Abstract][Full Text] [Related]
9. The molecular journey from ductal carcinoma in situ to invasive breast cancer.
Wiechmann L; Kuerer HM
Cancer; 2008 May; 112(10):2130-42. PubMed ID: 18383519
[TBL] [Abstract][Full Text] [Related]
10. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
11. Can dedicated breast PET help to reduce overdiagnosis and overtreatment by differentiating between indolent and potentially aggressive ductal carcinoma in situ?
Graña-López L; Herranz M; Domínguez-Prado I; Argibay S; Villares Á; Vázquez-Caruncho M
Eur Radiol; 2020 Jan; 30(1):514-522. PubMed ID: 31375867
[TBL] [Abstract][Full Text] [Related]
12. Optimal management of ductal carcinoma in situ of the breast.
Sakorafas GH; Farley DR
Surg Oncol; 2003 Dec; 12(4):221-40. PubMed ID: 14998563
[TBL] [Abstract][Full Text] [Related]
13. Ductal carcinoma in situ: a disease entity that merits more recognition.
Dereere E; Papadimitriou K; Tjalma W; Altintas S
Minerva Chir; 2015 Aug; 70(4):231-9. PubMed ID: 25916193
[TBL] [Abstract][Full Text] [Related]
14. A retrospective alternative for active surveillance trials for ductal carcinoma in situ of the breast.
Van Bockstal MR; Agahozo MC; Koppert LB; van Deurzen CHM
Int J Cancer; 2020 Mar; 146(5):1189-1197. PubMed ID: 31018242
[TBL] [Abstract][Full Text] [Related]
15. Current treatment trends and the need for better predictive tools in the management of ductal carcinoma in situ of the breast.
Martínez-Pérez C; Turnbull AK; Ekatah GE; Arthur LM; Sims AH; Thomas JS; Dixon JM
Cancer Treat Rev; 2017 Apr; 55():163-172. PubMed ID: 28402908
[TBL] [Abstract][Full Text] [Related]
16. Ductal carcinoma in situ (DCIS) of the breast: evolving perspectives.
Sakorafas GH; Tsiotou AG
Cancer Treat Rev; 2000 Apr; 26(2):103-25. PubMed ID: 10772968
[TBL] [Abstract][Full Text] [Related]
17. Risk of subsequent invasive breast cancer after a diagnosis of ductal carcinoma in situ (DCIS).
Cheung S; Booth ME; Kearins O; Dodwell D
Breast; 2014 Dec; 23(6):807-11. PubMed ID: 25270228
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora's box.
Lazzeroni M; Dunn BK; Pruneri G; Jereczek-Fossa BA; Orecchia R; Bonanni B; DeCensi A
Cancer Treat Rev; 2017 Apr; 55():1-9. PubMed ID: 28262606
[TBL] [Abstract][Full Text] [Related]
19. What quality-of-life issues do women with ductal carcinoma in situ (DCIS) consider important when making treatment decisions?
Mercieca-Bebber R; King MT; Boxer MM; Spillane A; Winters ZE; Butow PN; McPherson J; Rutherford C
Breast Cancer; 2017 Sep; 24(5):720-729. PubMed ID: 28247220
[TBL] [Abstract][Full Text] [Related]
20. Invasive breast cancer and breast cancer mortality after ductal carcinoma in situ in women attending for breast screening in England, 1988-2014: population based observational cohort study.
Mannu GS; Wang Z; Broggio J; Charman J; Cheung S; Kearins O; Dodwell D; Darby SC
BMJ; 2020 May; 369():m1570. PubMed ID: 32461218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
